他汀类药物治疗与威胁视力糖尿病视网膜病变预防的关联
这项基于台湾地区人群的队列研究纳入37 894例2型糖尿病合并血脂异常患者,比较使用与不使用他汀类药物的结局。倾向评分匹配后,他汀组糖尿病视网膜病变发生风险显著降低(HR 0.86;95% CI 0.81-0.91),增殖性糖尿病视网膜病变、玻璃体积血、牵拉性视网膜脱离和黄斑水肿风险及视网膜激光、玻璃体腔注射、玻璃体切除术需求均降低。
要点
- 他汀治疗与糖尿病视网膜病变总体风险降低相关(HR 0.86;95% CI 0.81-0.91)。
- 他汀治疗与增殖性糖尿病视网膜病变风险降低相关(HR 0.64;95% CI 0.58-0.70)。
- 他汀治疗与视网膜激光、玻璃体腔注射和玻璃体切除术需求降低相关。
核心结论
- 在台湾地区2型糖尿病合并血脂异常患者中,他汀治疗与糖尿病视网膜病变风险降低及威胁视力糖尿病视网膜病变治疗需求减少相关。
研究设计与样本
- 基于台湾地区全民健康保险研究数据库的人群队列研究,纳入1998年1月1日至2013年12月31日期间37 894例2型糖尿病合并血脂异常患者。
- 暴露定义为他汀治疗且药物持有率80%或以上、未使用其他降脂药物。
- 比较他汀组与非他汀组结局,采用倾向评分匹配,匹配后每组18 947例;他汀组平均随访7.6年,非他汀组平均随访7.3年。
主要发现
- 研究期间他汀组2004例(10.6%)、非他汀组2269例(12.0%)发生糖尿病视网膜病变。
- 他汀组糖尿病视网膜病变风险显著降低(HR 0.86;95% CI 0.81-0.91),非增殖性糖尿病视网膜病变HR 0.92(95% CI 0.86-0.99),增殖性糖尿病视网膜病变HR 0.64(95% CI 0.58-0.70)。
- 他汀组玻璃体积血HR 0.62(95% CI 0.54-0.71),牵拉性视网膜脱离HR 0.61(95% CI 0.47-0.79),黄斑水肿HR 0.60(95% CI 0.46-0.79)。
- 他汀组视网膜激光治疗HR 0.71(95% CI 0.65-0.77),玻璃体腔注射HR 0.74(95% CI 0.61-0.89),玻璃体切除术HR 0.58(95% CI 0.48-0.69)。
- 他汀治疗还与主要不良心血管事件风险降低(HR 0.81;95% CI 0.77-0.85)、新发糖尿病神经病变风险降低(HR 0.85;95% CI 0.82-0.89)及新发糖尿病足溃疡风险降低(HR 0.73;95% CI 0.68-0.78)相关。
关键数值与推荐
- 他汀暴露定义为药物持有率80%或以上且未使用其他降脂药物。
- 主要结局为任何分期糖尿病视网膜病变及威胁视力糖尿病视网膜病变的治疗。
- 倾向评分匹配后他汀组18 947例(女10 436例、男8511例;平均[SD]年龄61.5[10.8]岁),非他汀组18 947例(女10 430例、男8517例;平均[SD]年龄61.0[11.0]岁)。
临床怎么用
- 对于2型糖尿病合并血脂异常患者,他汀治疗可能与糖尿病视网膜病变风险降低及威胁视力病变治疗需求减少相关,可结合心血管风险评估综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Diabetic retinopathy is the leading cause of blindness in working-age adults. Studies have suggested that statins may reduce the risk of developing diabetic retinopathy. OBJECTIVE: To investigate the association between statin therapy and the development of diabetic retinopathy in patients with diabetes and dyslipidemia. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study, conducted among 37 894 Taiwanese patients between January 1, 1998, and December 31, 2013, used the National Health Insurance Research Database to identify patients with type 2 diabetes and dyslipidemia. Outcomes were compared between those taking statins and those not taking statins. Statistical analysis was performed from May 1 to 31, 2018. EXPOSURE: Statin therapy with a medication possession rate of 80% or more with no other lipid-lowering medications. MAIN OUTCOMES AND MEASURES: Any stage of diabetic retinopathy and treatments for vision-threatening diabetic retinopathy. RESULTS: Of 1 648 305 patients with type 2 diabetes, 219 359 were eligible for analysis over the study period, including 199 760 patients taking statins and 19 599 patients not taking statins. After propensity score matching, there were 18 947 patients in the statin group (10 436 women and 8511 men; mean [SD] age, 61.5 [10.8] years) and 18 947 patients in the nonstatin group (10 430 women and 8517 men; mean [SD] age, 61.0 [11.0] years), with a mean follow-up of 7.6 years for the statin group and 7.3 years for the nonstatin group. During the study period, 2004 patients in the statin group (10.6%) and 2269 patients in the nonstatin group (12.0%) developed diabetic retinopathy. Patients in the statin group had a significantly lower rate of diabetic retinopathy (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91), nonproliferative diabetic retinopathy (HR, 0.92; 95% CI, 0.86-0.99), proliferative diabetic retinopathy (HR, 0.64; 95% CI, 0.58-0.70), vitreous hemorrhage (HR, 0.62; 95% CI, 0.54-0.71), tractional retinal detachment (HR, 0.61; 95% CI, 0.47-0.79), and macular edema (HR, 0.60; 95% CI, 0.46-0.79) than the nonstatin group, as well as lower rates of interventions such as retinal laser treatment (HR, 0.71; 95% CI, 0.65-0.77), intravitreal injection (HR, 0.74; 95% CI, 0.61-0.89), and vitrectomy (HR, 0.58; 95% CI, 0.48-0.69), along with a smaller number of the interventions (retinal lasers: rate ratio, 0.61; 95% CI, 0.59-0.64; intravitreal injections: rate ratio, 0.68; 95% CI, 0.61-0.76; and vitrectomies: rate ratio, 0.54; 95% CI, 0.46-0.63). Statin therapy was also associated with lower risks of major adverse cardiovascular events (HR, 0.81; 95% CI, 0.77-0.85), new-onset diabetic neuropathy (HR, 0.85; 95% CI, 0.82-0.89), and new-onset diabetic foot ulcers (HR, 0.73; 95% CI, 0.68-0.78). CONCLUSIONS AND RELEVANCE: Statin therapy was associated with a decreased risk of diabetic retinopathy and need for treatments for vision-threatening diabetic retinopathy in Taiwanese patients with type 2 diabetes and dyslipidemia.
引用
- Kang EY, Chen TH, Garg SJ, et al. Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmol. 2019. PMID: 30629109. doi:10.1001/jamaophthalmol.2018.6399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。